Back to search
Recurrent, Epithelial Ovarian Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent, Epithelial Ovarian Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent, Epithelial Ovarian Cancer trials you may qualify forThe main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to p…
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituz…
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological cle…
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
This Phase 3 study will be conducted in different countries around the world with up to about 528 participants. The purpose of this study is to evaluate how we…
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come ba…
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indi…
This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how we…